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Genetic mutations and aging-associated oxidative damage underlie the onset and
progression of neurodegenerative diseases, like Parkinson’s disease (PD) and Machado-
Joseph disease (MJD). Natural products derived from plants have been regarded as
important sources of novel bioactive compounds to counteract neurodegeneration.
Here, we tested the neuroprotective effect of an ethanolic extract of rapeseed
pomace (RSP), a rapeseed (canola) oil production by-product, in C. elegans models
of MJD and PD. The extract, containing sinapine and other phenolics, restored motor
function of mutant ataxin-3 (ATXN3) animals (MJD) and prevented degeneration of
dopaminergic neurons in one toxin-induced and two genetic models of PD. Whole-
organism sensors of antioxidant and xenobiotic response activation revealed the
induction of phase II detoxification enzymes, including glutathione S- transferase (GST-
4) upon RSP extract supplementation. Furthermore in vivo pharmacogenetic studies
confirmed gst-4 is required for the therapeutic effect of RSP extract in the two disease
models. The results suggest that GST-4-mediated antioxidant pathways may constitute
promising therapeutic co-targets for neurodegenerative diseases and confirm the utility
of searching for bioactive compounds in novel sources, including food and agricultural
waste/by-products, such as RSP.
Keywords: rapeseed (canola) pomace, C. elegans, Parkinson’s disease, Machado-Joseph disease,
Spinocerebellar ataxia 3, antioxidant, gst-4, sod-3
INTRODUCTION
The number of people affected by neurodegenerative diseases has been increasing significantly
over the last few decades, due to the ever-growing world population and an increase in life
expectancy. Age is a major risk factor for neurodegeneration, hence the number of patients will
further increase and become a major health issue worldwide. This is further aggravated by the
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lack of effective prevention and/or disease-modifying
treatment strategies for these disorders. Drug discovery
efforts are thus a priority (Joyner and Cichewicz, 2011;
Ebrahimi and Schluesener, 2012).
Many neurodegenerative diseases, such as Alzheimer’s,
Parkinson’s, and Huntington’s as well as other polyglutamine
diseases, including Machado-Joseph disease (MJD), or
Spinocerebellar ataxia type 3 (SCA3) have in common their
association with aging, protein aggregation and oxidative
stress (Gandhi and Abramov, 2012; Kim et al., 2015). In both
familiar and sporadic forms of PD, mitochondrial dysfunction,
neuroinflammation and environmental factors contribute to the
susceptibility of dopaminergic neurons. When the production
of Reactive Oxidative Species (ROS) surpasses the cellular
antioxidant activity, the continuation of an oxidation state
triggers cellular damage and causes neuronal loss, a process that
is generally linked to normal aging but accelerated in disease
states (Blesa et al., 2015). The involvement of oxidative stress in
MJD is less well documented, however, it is thought that ATXN3
plays an important role in regulating the FOXO4-dependent
antioxidant stress response via the manganese superoxide
dismutase (SOD2), which is disrupted upon expression of the
mutant protein. This suggests that a decreased antioxidative
capacity and an increased susceptibility toward oxidative stress
contribute to neuronal cell death in MJD (Araujo et al., 2011). In
fact, MJD patients show decreased antioxidant defense capacity,
as a result of increased ROS generation and decreased levels of
glutathione peroxidase (de Assis et al., 2017), as well as reduced
thiol levels (glutathione and thioredoxins) and increased DNA
damage (Pacheco et al., 2013). This suggests that approaches
to improve the cellular antioxidant capacity could lead to
effective therapeutics.
Previous research on plant extracts and isolated compounds
from plants (natural products) had shown promising results
in both in vitro and in vivo models of normal aging (Ryu
et al., 2016) as well as in models of neurodegenerative diseases
(Joyner and Cichewicz, 2011; Ebrahimi and Schluesener, 2012;
Pohl and Kong Thoo Lin, 2018). HPLC-MS/MS analysis of
RSP extracts revealed the presence of different secondary
metabolites, such as phenolic acids, benzaldehydes, amines,
indoles, flavonoids and coumarins, sinapine being the most
abundant secondary metabolite (Pohl et al., 2018; Yates et al.,
2019). Sinapine is a known acetylcholinesterase inhibitor
due to its structural similarity to acetylcholine (Ferreres
et al., 2009) and has neuroprotective effects and lifespan
increasing properties in several model systems (Li and Gu,
1999; Yang and He, 2008; Fu et al., 2016). We have
previously shown the antioxidant and radical scavenging
activity of the ethanolic rapeseed pomace (RSP) extract
in vitro. In addition to the in vitro antioxidant activity, both
the RSP extract and sinapine exhibited acetylcholinesterase
inhibition activity and protected plasmid DNA from oxidative
stress induced DNA damage in vitro (Pohl et al., 2018;
Yates et al., 2019).
Our previous results suggested the direct antioxidant activity
of the RSP extract. Direct antioxidants are redox active,
short-lived and are consumed or chemically modified during
the process of their antioxidant activity. They need to be
regenerated or replenished for continuous activity. However, at
certain concentrations they can also show pro-oxidant activity
(Dinkova-Kostova and Talalay, 2008). In comparison, indirect
antioxidants can activate antioxidant pathways, e.g., Kelch Like
ECH Associated Protein 1/Nuclear factor (erythroid-derived
2)-like 2/antioxidant response elements (Keap1/Nrf2/ARE) in
humans. This causes transcriptional induction of a variety of
cytoprotective proteins, also known as phase II detoxification
enzymes. For the activation of these pathways, the indirect
antioxidants are not sacrificed and hence have a longer half-
life (Dinkova-Kostova and Talalay, 2008; Christensen and
Christensen, 2014). Different indirect antioxidants have been
found in plants, such as curcumin in turmeric, carnosol and
carnosic acid in the herb rosemary (Martin et al., 2004; Takahashi
et al., 2009) and sulforaphane which is found in plants of the
Brassicaceae family such as broccoli, cauliflower and cabbage
(Dinkova-Kostova and Talalay, 2008; Visalli et al., 2017). While
inducing cytoprotective proteins, some indirect antioxidants also
act as direct antioxidants. By doing so they fulfill both roles,
they can decrease ROS immediately and induce responses, which
might have cytoprotective effects over a longer period of time
(Dinkova-Kostova and Talalay, 2008).
In this work, to determine the in vivo antioxidant activity
of RSP extract and its potential for the prevention of
neurodegenerative diseases, the model organism C. elegans was
used. Due to its numerous advantages (easy of culture in large
numbers, a short life span and a well characterized nervous
system, as well as its amenability to genetic manipulation and
its transparency, even in adult stages), it is commonly used in
neuroscience-related studies (Alexander et al., 2014; Chen et al.,
2015; Ma et al., 2018). We focused on two neurodegenerative
diseases – PD and MJD – that have been associated with
intracellular protein aggregation and in which oxidative stress
has proven to be relevant. C. elegans models for both disorders
have previously been created and employed for the search of
potential treatments (Teixeira-Castro et al., 2011, 2015; Li et al.,
2016; Manalo and Medina, 2018) and were used here to test the
therapeutic potential of RSP extract, as a first in vivo evidence.
MATERIALS AND METHODS
Strains and General Maintenance
A list of strains together with their abbreviations, genotype
and source is given in Supplementary Table S1. All strains
were cultured and observed using standard methods (Brenner,
1974) unless otherwise stated. C. elegans grew on Nematode
Growth Medium (NGM) plates seeded with Escherichia coli
OP50 strain at 20◦C. All the strains were backcrossed to Bristol
strain N2 six to eight times. The UA44 (Pdat-1:GFP; Pdat-
1:α-syn) and UA57 (Pdat-1:GFP; Pdat-1:CAT-2) strains were
generously provided by Guy Caldwell (University of Alabama).
The MJD related strains (AT3q14, AT3q75, and AT3q130)
were previously described (Teixeira-Castro et al., 2011) and
double mutant strains [AT3q130;gst-4(ko) and α-syn;gst-4(ko)]
were generated using common breeding techniques (Fay, 2013).
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The remaining strains were provided by the Caenorhabditis
Genetics Center (CGC).
Rapeseed Pomace Extracts and Sinapine
The RSP extract was prepared as previously described (Pohl et al.,
2018; Yates et al., 2019). Although our previous studies have
shown small batch-to-batch variability in chemical composition
in extracts from different harvest years (Pohl et al., 2018),
in this work several extractions were performed, and the
obtained extracts collected, combined, homogenized, vacuum
packed and stored at −80◦C. Sinapine thiocyanate was obtained
from ChemFaces, China (CFN90624) and was used without
further purification.
C. elegans Drug Toxicity Assay
The toxicity of distinct concentrations of RSP extract in vivo was
determined in the wild-type N2 Bristol strain, using the food
clearance assay (Voisine et al., 2007). The assay was performed
as previously described (Voisine et al., 2007; Teixeira-Castro
et al., 2015) in liquid culture in 96-well plate format using
concentrations from 0.01–5.0 mg/mL of RSP extract and 0.001–
1.0 mg/mL sinapine, using DMSO as the drug vehicle at a
final concentration of 1%. Animals treated with 1% and 5%
DMSO were used as a non-toxic (vehicle control) and as a toxic
concentration control, respectively.
Motor Performance and Mutant ATXN3
Aggregation in the C. elegans MJD
Model Treated With RSP Extract
AT3q130 animals were treated with concentrations of RSP
extract and sinapine ranging from 0.1 to 5.0 mg/mL and 0.001–
1.0 mg/mL, respectively, in liquid culture in 96-well format as
described for the toxicity assay (Voisine et al., 2007). The motility
assay was performed as previously described (Teixeira-Castro
et al., 2011), using C. elegans strains expressing WT (AT3q14)
and mutant ATXN3 (AT3q130) proteins in their nervous system,
as well as N2 as control. In vivo confocal dynamic imaging and
quantification of mutant ATXN3 aggregates for the RSP extract
treatment was conducted as previously described (Teixeira-
Castro et al., 2011) using an Olympus FV1000 (Japan) confocal
microscope, under a 60x oil (NA = 1.35) objective. Z-series images
were acquired for vehicle (1% DMSO) and RSP extract-treated
(4 mg/mL) animals, using a 515 nm laser excitation line for
yellow fluorescent protein (YFP). Regarding quantification of
the mutant ATXN3 aggregates, two parameters were measured:
area of aggregates/total area and number of aggregates/total area
in three repeated experiments. The RSP extract concentration
chosen for the in vivo imaging (4 mg/mL) was based on the initial
motility results.
Quantitative Analysis of Dopaminergic
Neuronal Degeneration in the 6-OHDA
C. elegans PD Model Treated With RSP
Extract
The experimental procedure for 6-hydroxydopamine (6-OHDA)
exposure was adapted from Cao et al. (2005) with minor
modifications, using the strain BZ555 that expresses green
fluorescent protein (GFP) in all dopaminergic neurons. Briefly,
an age synchronized egg population was obtained via bleaching
(Stiernagle, 2006). Approximately 200 eggs were pipetted onto
NGM plates, freshly seeded with freeze/thaw inactivated OP50
containing DMSO (1%, vehicle control) or RSP extract (4 mg/mL)
(day 0). Approximately 48 h later (day 2), L2-L3 worms were
washed off the plates and washed 2–3 times in distilled water
(dH2O) containing 1% Luria broth (LB) until solution was clear
(no remaining OP50). Worms were resuspended in approximately
500 µL of dH2O with 1% LB. In a 12-well plate, 250 µL of 6-
OHDA (final concentrations 10 and 25 mM), 250µL ascorbic acid
(final concentrations 2 and 5 mM, respectively) and 500 µL of the
worm solution were incubated for 1 h at∼50 rpm on a Grant-Bio
POS-300 orbital shaking platform. After this time, the worms were
diluted and washed 2–3 times in dH2O with 1% LB. Thereafter,
BZ555 worms were transferred back onto respective vehicle or
RSP extract seeded plates. On day 5, approximately 72 h after 6-
OHDA treatment, worms were prepared for confocal imaging, as
described above. Dopaminergic (DAergic) neurons were counted
in 10–12 animals and representative pictures of each condition
were obtained. The experiment was repeated three times (total
number of worms scored n ≥ 30).
Quantitative Analysis of Dopaminergic
Neuronal Loss in Alpha-Synuclein and
CAT-2-Mediated PD Model Treated With
RSP Extract
Age-synchronized populations of BZ555 (Pdat-1:GFP), UA44
(Pdat-1:GFP; Pdat-1:α-syn) and UA57 (Pdat-1:GFP; Pdat-1:CAT-
2) strains were obtained via egg-laying. Briefly, gravid animals
were picked onto plates seeded with freeze/thaw inactivated
OP50 supplemented with vehicle (1% DMSO) and RSP extract
(4 mg/mL) and left to lay eggs for 1–2 h before being removed
from plates (day 0). After day 3, animals were transferred
daily to fresh plates to avoid progeny. At day 7 and/or 10,
worms (N = 10–12) were prepared for confocal microscopy as
described above. Intact dopaminergic (DAergic) neurons were
counted, and representative pictures of each condition were
taken. The experiment was repeated independently three times
(total number of worms scored n ≥ 30).
Assessment of Antioxidant Response
Induction Using Reporter Strains for
gst-4, sod-3 and gcs-1 Genes
CL2166 [(pAF15)gst-4p:GFP:NLS], CF1553 [(pAD76)
sod-3p:GFP + rol-6(su1006)], LD1171 [(gcs-1p:GFP + rol-
6(su1006)] strains were grown in NGM plates seeded with
freeze/thaw inactivated bacteria and RSP extract (4 mg/mL)
until day 4 (∼96 h after hatching). Worms were prepared for
fluorescence microscopy, by preparing 3% agar slides and adding
a drop of sodium azide (2 mM) in addition to 10–12 worms
per slide. Worms were oriented using an eye lash, excess azide
was removed and the worms were covered with a cover slide
and sealed with 3% agar. Brightfield (1.662 ms exposure time,
ISO1600) and fluorescence (ISO1600, GFP filter) images of
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vehicle and RSP extract treated animals were acquired in an
Olympus Microscope BX61 (10× objective) using the same
respective settings. Fluorescence exposure time was set to a
value where vehicle treated worms were barely visible and the
same settings were used to analyze the RSP treated worms.
Fluorescence intensity of each worm was measured using Fiji
(ImageJ, 1.51n), divided by the total area of the respective animal
and normalized to the mean of the vehicle treated worms. The
experiment was repeated three times independently, n ≥ 10
being the number of animals analyzed per treatment in each
experiment (per condition). For the purpose of showing the
results, the same level of brightness and contrast was applied
to vehicle- and RSP-treated animals, with no impact in the
fluorescence quantification of the images.
Statistical Analysis
All statistical analyses were performed using GraphPad
Prism 7 (Version 7.01) or SPSS 25.0 (SPSS Inc.). Continuous
variables were tested for normal distribution (Shapiro–Wilk
or Kolmogorov–Smirnov normality test), for homogeneity
of variance (Levene’s test) and outliers; and were then
analyzed with one-way or two-way ANOVA, using Bonferroni’s,
Dunnett’s or Tukey’s multiple comparison analysis for post hoc
comparison. Non-continuous variables were analyzed through
non-parametric Mann–Whitney or Kruskal–Wallis (with
Bonferroni’s multiple comparison correction) tests, for two
or more groups, respectively. For the comparison of effect
sizes of RSP extract and sinapine treatments of experiments
undertaken in independent trials, the Hedge’s test was done
in R (version 3.6.1, package “effsize” version 0.7.6). A critical
value for significance of p ≤ 0.05 was applied throughout the
study. All experiments were run at least in triplicate (n ≥ 3) and
data presented are showing mean ± standard deviation unless
otherwise stated.
RESULTS
RSP Extract Shows No Toxic Effect in
C. elegans
RSP extract safety concentration range in C. elegans was
determined by the food clearance assay (Voisine et al., 2007).
A compound is considered safe to C. elegans if it causes no
changes in animal growth, survival, and number of offspring,
which can be measured indirectly by determining the rate of
food consumption of the E. coli bacteria (OP50). The profile
of the bacteria optical density curves obtained for all the tested
concentrations of the RSP extract resembled that of vehicle
treated animals (1% DMSO control, known to be safe) (Teixeira-
Castro et al., 2015; Figure 1). The OP50 food source was cleared
in an expected manner, starting on day 2–3 when worms were on
the L4 molt. The further decrease in optical density on day 4 was
associated with an increased number of worms in the wells, due
to the appearance of progeny. There was no change in bacteria
density upon 5% DMSO treatment, confirming its toxic effects.
In summary, the RSP extract was considered safe to C. elegans at
concentrations up to 5 mg/mL.
Improvement of Motor Impairments of
an MJD C. elegans Model With RSP
Extract Treatment Independently of
ATXN3 Aggregation Load
To determine whether the RSP extract supplementation has
therapeutic value for MJD, we used a C. elegans model of
ATXN3 neurotoxicity (AT3q130) in which mutant ATXN3
proteins expressed in neurons, caused motility defects and
aggregation (Teixeira-Castro et al., 2011). The results presented
in Figure 2A demonstrated a concentration-dependent
improvement in motility of the RSP-treated AT3q130 animals.
Concentrations ranging from 1.00–5.00 mg/mL showed a very
strong and significant improvement (p ≤ 0.001). However,
lower concentrations of 0.75 mg/mL (p ≤ 0.01) and 0.50–
0.25 mg/mL (p ≤ 0.05) also significantly improved the animals’
motor capacity. Only the lowest RSP extract concentration
of 0.1 mg/mL showed no effect on the phenotype when
administered to the animals. Treatment of AT3q130 animals
with RSP extract at 4 mg/mL restored their motor function
close to the level of WT ATXN3 expressing animals (AT3q14),
hence this concentration was used in further experiments.
To determine whether this motility improvement was disease
specific, we also treated WT (N2) and AT3q14 animals with
4 mg/mL of RSP extract. The results confirmed a disease-specific
effect since neither the N2 nor the AT3q14 motor performance
changed upon treatment (Figure 2B).
As sinapine has been determined to be the most abundant
compound present in the RSP extract (Yates et al., 2019), we
next tested it for toxicity and disease modifying properties in
AT3q130 animals. Sinapine showed no toxicity toward C. elegans
up to 1 mg/mL (Supplementary Figure S1A) and had a beneficial
effect in the disease model, although its effect in motility
improvement was smaller (Hedge’s g = −3.967) than the RSP
extract (Hedge’s g = −5.585) (Supplementary Figure S1B and
Figure 2A), suggesting that additional components of the extract
are contributing to its therapeutic effect. Hence, subsequent
analyses were carried out using the whole RSP extract.
In MJD, the mutant ATXN3 (mATXN3) protein forms
aggregates within affected regions of the patient’s brain. This is
also observed in the C. elegans AT3q130 model (Teixeira-Castro
et al., 2011), which shows mATXN3 aggregation in neuronal cells
in the head region as well as in the dorsal and ventral nerve
cords of the animals. Confocal imaging revealed no significant
change in the number or area of mATXN3 protein aggregates in
the head of treated animals compared to the untreated animals
(Figures 2C,D), which demonstrates an uncoupling of RSP
extract effect between these two main hallmarks of MJD, neuronal
dysfunction and mutant protein aggregation.
RSP Extract Treatment Protects From
6-OHDA-Induced Dopaminergic
(DAergic) Neuronal Loss
Given the promising results in the polyglutamine disease
model described above, the effect of the RSP extract was next
evaluated in a chemically induced model of PD. Transgenic
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FIGURE 1 | RSP extract (0.01–5.0 mg/mL) shows no toxic effect in C. elegans. Toxicity was assessed using the food clearance assay. The optical density of the
OP50 suspension with RSP extract-treated animals (N2) at the concentrations depicted, was measured daily. The mean optical density (OD) was calculated for each
day from triplicate samples and plotted over time. Control DMSO (1%) corresponds to drug vehicle and DMSO at 5% was used as positive (toxic compound) control,
n = 5 (independent experiments).
FIGURE 2 | Improvement of motor impairments of the MJD C. elegans model with RSP extract treatment is independent of ATXN3 aggregation load.
(A) Locomotion defective behavior of MJD (AT3q130) animals, comparison between treated (RSP extract 0.1–5.0 mg/mL), untreated animals (1% DMSO solvent
control), wild type (N2) and AT3q14 controls (1% DMSO). Statistical significant difference was determined using One-way ANOVA and Dunnett’s multiple comparison
analysis compared to AT3q130 control: ∗∗∗p ≤ 0.001, ∗∗p ≤ 0.01, ∗p ≤ 0.05; n = 5. (B) Comparison of locomotion defective behavior of N2, AT3q14, and AT3q130
untreated (1% DMSO vehicle control) and RSP extract treated (4 mg/mL) animals. Statistical significant difference determined using Two-way ANOVA and Tukey’s
multiple comparisons test compared to untreated (1%DMSO) control: ∗∗∗p ≤ 0.001, ns-not significant, n = 6. (C) Confocal imaging of head region of AT3q130 strain
treated with RSP (4 mg/mL, right) in comparison to vehicle control (1% DMSO, left). Confocal microscopy pictures are representative for the three independent
experiments. (D) Aggregation load (number and area of aggregations) of AT3q130 animals upon treatment with RSP extract (4 mg/mL) compared to solvent control
(1% DMSO). Values shown are the mean (normalized to vehicle treated control) of 10 or more animals per group; number of experiments n = 3, no significant
difference, p > 0.05 (unpaired t-test). Data normalized to the 1% DMSO control. Scale bar 50 µm in all represented pictures.
animals expressing GFP proteins under the regulation of
the dopamine transporter promoter (Pdat-1:GFP) in all 8
hermaphrodite dopaminergic (DAergic) neurons (Figure 3A)
were exposed to a mixture of 6-OHDA and ascorbic acid
(as stabilizer) for 1 h. After 72 h, animals treated with 10
and 25 mM of 6-OHDA showed a clear loss of DAergic
neurons (Figures 3B,C,F), compared to vehicle-treated
control animals (Figures 3A,F) (p ≤ 0.001): in vivo dynamic
imaging showed intact cell bodies and processes of the
DAergic neurons of vehicle-treated GFP-expressing animals
(Figure 3A), contrasting with a 6-OHDA concentration
dependent increase in the blobbing of neuronal processes, and
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FIGURE 3 | Protective effects of RSP extract supplementation (4 mg/mL) on DAergic neurodegeneration in C. elegans. C. elegans strain with GFP expression in all
DAergic neurons (Pdat-1:GFP) grown in media supplemented with 1% DMSO (solvent control) and treated with (A): 0 mM 6-OHDA and 0 mM AA, (B): 10 mM
6-OHDA and 2 mM AA, (C): 25 mM 6-OHDA and 5 mM AA. C. elegans strain expressing GFP proteins in all DAergic neurons (Pdat-1:GFP) grown in media
supplemented with (D,E) 4 mg/mL RSP extract pre- and post- treated with (D): 10 mM 6-OHDA and 2 mM AA, (E) 25 mM 6-OHDA and 5 mM AA. The fluorescence
signals of DAergic neurons in the animals’ head (CEPs and ADEs) were photographed at 60× magnification using confocal fluorescence microscopy. Scale bar
50 µm in all represented pictures. (F) Total number of DAergic neurons were scored for each condition. Data are expressed as the median ± 10–90 percentile, with
results obtained from three independent experiments (n = 3 with ≥ 10 animals per treatment). Significant differences between conditions were determined by
non-parametric Kruskal–Wallis test and outlier analysis. #p < 0.05, ###p < 0.001 compared with vehicle alone (no 6-OHDA), ns, ∗p < 0.05, ∗∗p < 0.01, and
∗∗∗p < 0.001 compared with respective 6-OHDA concentration control. 6-OHDA: 6-hydroxydopamine; AA: ascorbic acid; DAergic-dopaminergic neurons.
in the loss of cell bodies (Figures 3B,C). The four cephalic
neurons (CEPs) were most susceptible to 6-OHDA treatment
(Supplementary Figure S2).
When comparing the 1% DMSO with the 4 mg/mL
RSP extract treated worms, there was a clear beneficial
effect of the treatment (Figures 3B–E) for both 6-OHDA
concentrations. Upon supplementation with RSP extract,
more animals showed intact cell bodies and processes,
although in some neurons the rounding of the cell body
(Figure 3, arrowheads) was still visible upon treatment.
This was confirmed when analyzing the total number of
DAergic neurons (Figure 3F) as well as the CEP neurons
alone (Supplementary Figure S1). These results suggest that
supplementation with RSP extract protects against toxin-induced
loss of DAergic neurons in vivo.
RSP Extract Treatment Prevents DAergic
Neuronal Loss in Genetic Models of PD
We then tested the effect of RSP extract treatment in genetically
modified nematodes that were also previously described to mimic
various aspects of PD neuropathology. Expression of human
α-synuclein proteins (α-syn), in combination with GFP proteins,
in the 8 C. elegans DAergic neurons induced neuronal death at
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FIGURE 4 | Supplementation with RSP extract suppressed loss of DAergic neurons mediated by alpha-synuclein and tyrosine hydroxylase overexpression in
C. elegans. Confocal imaging and quantification of total number of DAergic neurons in Pdat-1:GFP animals (A, day 7 and G, day 10), in Pdat-1:GFP; Pdat-1:α-syn
(B, day7 and H, day 10) and in Pdat-1:GFP; Pdat-1:cat-2 (C, day7 and I, day 10) vehicle treated (1% DMSO) animals, as well as in Pdat-1:GFP; Pdat-1:α-syn (D,
day7 and J, day 10) and in Pdat-1:GFP; Pdat-1:cat-2 (E, day 7 and K, day 10) RSP extract (4 mg/mL) treated animals. Quantification of total number of DAergic
neurons is shown in F (day 7) and L (day 10). Confocal microscopy pictures represent the head region of C. elegans and the pictures are representative of three
independent experiments. Data is shown as the median ± 10–90 percentile with results obtained from three independent experiments (n = 3 with ≥ 10 animals per
treatment). Significant differences between strains and treatment were determined by Kruskal–Wallis analysis, after outlier analysis: ns no significant difference.
###p < 0.001 compared with Pdat-1:GFP; ns ∗∗∗p < 0.001 compared with respective vehicle treated strain control. Scale bar 50 µm in all represented pictures.
day 7 and 10 of life (Cao et al., 2005; Cooper et al., 2006; Büttner
et al., 2014). Overexpression of cat-2, a gene which encodes
tyrosine hydroxylase, the limiting enzyme for dopamine synthesis
in C. elegans, leads to increased intracellular levels of dopamine
(Cao et al., 2005). As with α-synuclein, its overexpression is
known to cause the degeneration of DAergic neurons in older
animals. In cat-2 overexpression animals, loss of DAergic neurons
can also be detected by the co-expression of GFP in DAergic
neurons (Cao et al., 2005; Masoudi et al., 2014).
Control animals expressing only GFP proteins in all DAergic
neurons showed the presence of most neurons as well as the 4
dendrites associated with the 4 CEP neurons, heading to the front
of the worm (Figures 4A,B; 7 days old animals and Figures 4G,H
10 days old animals). In contrast, animals overexpressing α-
syn and CAT-2 proteins showed a significant loss of DAergic
neurons and their processes on days 7 (Figures 4A,C,D) and
10 (Figures 4G,I,J). Animals treated with RSP extract for
the duration of the experiment, showed an increase in the
number of preserved DAergic cell bodies and dendrites, in
particular for the CEPs, at day 7 (Figures 4A,E,F) and 10
(Figures 4G,K,L) indicating that the RSP extract treatment
suppresses DAergic neuronal loss in the genetic PD model, as
seen in the chemically induced model.
Activation of Antioxidant Pathways by
RSP Extract Treatment
To test the hypothesis that the antioxidant properties of the
RSP extract may contribute to the observed neuroprotective
effect in C. elegans models of neurodegenerative diseases, we
determined whether the RSP extract had the potential to
activate antioxidant pathways, using C. elegans reporter strains
for the gst-4, gcs-1 and sod-3 genes. GST-4 which encodes
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FIGURE 5 | RSP extract supplementation activated transcriptional activity of gst-4 and sod-3, but not of gcs-1 gene promoters in C. elegans reporter strains.
Brightfield and widefield fluorescence images of vehicle-(1% DMSO) and RSP-(4 mg/mL) treated Psod-3:GFP (A), Pgst-4:GFP (B) and Pgcs-1:GFP (C) animals.
Graphical results shown in (D) represents the GFP fluorescence intensity divided by the total area of each worm (n ≥ 9) normalized to the respective 1% DMSO
control. Statistical comparison was done via two-way ANOVA and Bonferroni’s multiple comparisons test after Shapiro–Wilk normality test and outlier analysis, graph
shows a representative example of three experimental replicates (n = 3). ns, no significant difference and ∗∗∗p < 0.001 compared with respective control. The
pictures presented are from the same experimental day. Time of exposure is maintained constant in vehicle- and RSP-treated animals. Fluorescence intensity of
each worm was measured using Fiji (ImageJ, 1.51n) and divided by the total area of the respective animal and normalized to the mean of the vehicle treated worms.
Scale bar 100 µm in all represented pictures.
for the drug-metabolizing enzyme glutathione S-transferase 4
and gcs-1, the phase II detoxification enzyme gamma-glutamyl
cysteine synthetase, are involved in glutathione metabolism and
biosynthesis, respectively. Both genes are downstream targets
of the transcription factor SKN-1 (Nrf-2 ortholog) (Hoeven
et al., 2011). sod-3 codes for the mitochondrial manganese
superoxide dismutase, which converts the ROS superoxide into
hydrogen peroxide. The transcriptional activity of these genes
was measured indirectly by the expression of GFP. The results
showed a modest but significant induction of the transcriptional
activity of the sod-3 gene promoter upon RSP treatment
(Figures 5A,D). Pgst-4:GFP animals show a three-fold induction
of GFP fluorescence upon RSP extract treatment (Figures 5B,D),
but no changes in the gcs-1 promoter activity of Pgcs-1:GFP
animals (Figures 5C,D) were observed in treated animals when
compared with vehicle.
Suppression of α-Synuclein- and Mutant
ATXN3-Mediated Neurotoxicity by RSP
Extract Treatment Is Dependent on
GST-4
To determine whether the beneficial effects of RSP extract
treatment in the C. elegans models of PD and MJD pathogenesis
were mediated by GST-4, we assessed the effect of RSP extract
supplementation in a gst-4 deletion background [gst-4(ko)].
Ablation of gst-4 per se did not alter the α-syn-mediated
neuronal loss (Figure 6A) or mutant ATXN3-mediated motor
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FIGURE 6 | GST-4-dependent rescue of MJD and PD phenotypes by RSP extract supplementation. (A) DAergic neuron loss in Pdat-1:GFP, Pdat-1:α-syn and in
Pdat-1:α-syn;gst-4(ko) animals comparing treated (RSP extract (4 mg/mL) and untreated [DMSO (1%)] conditions. Graph: 2 independent experiments (n) were
conducted with 12 animals per group. Statistical significant difference was determined using the non-parametric Kruskal–Wallis test ∗p < 0.05 compared to
untreated α-syn, ###p < 0.001 compared to Pdat-1::GFP, ns compared to untreated α-syn;gst-4(ko). Images: confocal imaging of DA neurons, scale bar 50 µm.
(B) Motility assay comparison between WT, AT3q130, AT3q130; gst-4(ko) and gst-4(ko) strains. At least 200 animals were assayed per experiment, in five
independent experiments (n = 5). Significant differences between strains and treatment were determined by one-way ANOVA and Bonferroni’s multiple comparison
analysis, after Shapiro–Wilk normality test and outlier analysis: ∗∗∗p < 0.001 compared with respective control.
impairments (Figure 6B). However, RSP extract treatment failed
to suppress α-syn-mediated loss of DAergic neurons in the
absence of gst-4 (Figure 6A), suggesting the importance of GST-4
activity in the extract’s mechanism of action.
A similar analysis made on AT3q130 animals in the
background of gst-4 ablation [AT3q130; gst-4(ko)] (Figure 6B)
also indicated the role of GST-4 activation in the positive
effect of the RSP extract in this disease model. AT3q130
animals showed significant motility improvements upon RSP
extract treatment (4 mg/mL), whereas the AT3q130; gst-
4(ko) double mutants showed no significant improvement
in motor capacity compared to the vehicle control (1%
DMSO). Taken together, these results support the idea that
neuroprotection and suppression of proteotoxicity by RSP extract
supplementation is dependent on the modulation of GST-4
activity in C. elegans.
DISCUSSION
In this study we describe the potential use of RSP extract to
prevent neuronal dysfunction and neurodegeneration in vivo
using transgenic C. elegans strains expressing mutant ATXN3,
α-synuclein and tyrosine hydroxylase to mimic MJD and PD
pathogenesis, respectively. In support of the findings, the loss
of DAergic neurons was also rescued by RSP supplementation
in a well-established toxin-induced model of PD. These models
were previously employed to search potential treatments for
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these disorders, which were then proven effective in higher
model organisms (Teixeira-Castro et al., 2011, 2015; Manalo and
Medina, 2018; Yan et al., 2018).
Although MJD and PD are distinct clinical entities, they share
common etiologies, such as the formation of protein aggregates
(Dimitriadi and Hart, 2010) and some neuropathological
mechanisms, including their link to mitochondrial dysfunction,
oxidative stress and endoplasmic reticulum stress (Chakraborty
et al., 2013; Chege and McColl, 2014). Increasing evidence
suggested a possible interaction between proteins that have
been classically associated to distinct neurodegenerative diseases
(Wszolek et al., 2004; Lattante et al., 2014). Some of these diseases
also share clinical and neuropathological features, an example
being the slow movement or bradykinesia, that characterizes PD
patients, and is also part of the clinical presentation of a subset of
MJD patients. Some MJD patients also present parkinsonism with
a positive response to levodopa (L-DOPA) (Bettencourt et al.,
2011). Furthermore, α-synuclein aggregates were detected in the
substantia nigra of MJD models (Alves et al., 2008; Noronha
et al., 2017). This evidence suggests that common molecular
and cellular pathways might underlie similarities between disease
phenotypes, and that therapeutic compounds targeting those
common aspects may be effective for both diseases.
Our study revealed a consistent neuroprotective effect of RSP
extract in different models. In MJD, RSP extract supplementation
restored motor function of the mutant ATXN3 animals, although
not linked to a change in the ATXN3 aggregation load detected in
live neurons. This dissociation between the impact on neuronal
dysfunction and on ATXN3 aggregation was previously seen in a
small molecule drug library screening based on the same animal
model (Teixeira-Castro et al., 2015), and is consistent with many
previous findings supporting such a dissociation for this and
other polyglutamine diseases (Silva et al., 2011; Beam et al., 2012).
Sinapine treatment contributes to the attenuation of the motor
impairments of mutant ATXN3-expressing animals upon RSP
supplementation, however, other components of the extract may
also play a role, with potential synergic effects.
To our knowledge there have been no previous reports
on the preventive effect of RSP extract in C. elegans models
of neurodegenerative disease. However, other plant extracts
and compounds isolated from plants have been investigated
in C. elegans PD models. For example, the natural occurring
polyamine spermidine rescued α-synuclein-induced loss of
DAergic neurons (Büttner et al., 2014), through autophagy
induction. A methanolic extract of red seaweed (Chondrus
crispus) (Sangha et al., 2013) showed promising neuroprotective
effects and decreased α-synuclein aggregation in muscle cells.
These effects were associated with enhanced tolerance to
oxidative stress but not to heat stress and with increased
expression of sod-3 and skn-1, the C. elegans ortholog of Nrf2 (Liu
et al., 2015). In a MPP+-induced PD model, the extract of Korean
mountain ash (Sorbus alnifolia) restored C. elegans viability and
prevented neuronal loss (Cheon et al., 2016). That extract also
showed neuroprotection upon CAT-2 overexpression, but with
no impact on α-synuclein aggregation (Cheon et al., 2016).
Studies using natural occurring compounds for the potential
treatment of polyglutamine diseases are less common. However,
epigallocatechin-3-gallate (EGCG, a tea catechin) suppressed
mutant ATXN3-mediated neurotoxicity with no impact on
aggregation (Bonanomi et al., 2014). The natural product
icariside II, a flavonol extracted from the Epimedium plant family,
in contrast, ameliorated protein aggregation and proteotoxicity-
mediated paralysis in a polyQ35 C. elegans model and increased
the levels of sod-3 and of hsp-12.3, a small heat shock protein that
was described to prevent aggregate formation (Cai et al., 2011).
Other plant secondary metabolites that induce the expression of
GST-4 and of other enzymes involved in glutathione biosynthesis
and metabolism, also reduce ROS accumulation, protect against
oxidative stress and prolong organism lifespan (Hsu et al., 2012;
Ogawa et al., 2016).
Overall, the impact of natural compounds on proteotoxicity
has been primarily associated to their antioxidant properties since
many studies reported activation of antioxidant genes/pathways.
However, those studies fail to show a dependence of these
proteins on their therapeutic role. Here, we report the induction
of GST-4 expression by RSP extract and the lack of efficacy of
RSP supplementation upon GST-4 ablation. Nevertheless, we do
not exclude the role of additional cellular targets (e.g., SOD-3,
other GSTs and other pathways), neither do we imply a direct
dependency on the antioxidant activity of GST-4 in vivo on
the therapeutic role of RSP extract. Endogenous modification of
the catalytic domain/residue of GST-4 (e.g., by using CRISPR)
would be necessary (Babbitt, 2000; Shi et al., 2015) for further
elucidation. Other possible mechanisms of action remain to be
tested for the RSP extract, including their role in the maintenance
of the protein homeostasis capacity in neuronal cells (Balch
et al., 2008) or in the increase of dopamine D2-like receptor
(DOP2R) activation/availability (Manalo and Medina, 2018). To
further understand the alteration the RSP extract is causing
in transgenic C. elegans strains and to elucidate its role in
MJD and PD, multi-omics combination including metabolomics,
transcriptomics and proteomics would be a worthy strategy to
adopt in the future.
In humans, glutathione transferases play crucial functions in
the metabolism of xenobiotics and of endogenous compounds.
In addition to their role in the detoxification of oxidative stress
products, GST are also involved in the degradation of aromatic
amino acids, synthesis of steroid hormones, synthesis and
inactivation of eicosanoids and in the modulation of signaling
pathways through their role in the metabolism of endogenous
lipid mediators (reviewed in Hayes et al., 2005). The proposed
human ortholog of GST-4 is hematopoietic prostaglandin D
synthase (HPGDS) (Wormbase (Version WS272))1. This is a
bifunctional enzyme of the sigma class of the glutathione-
S-transferase family and catalyzes the conversion of PGH2
to PGD2 as well as the conjugation of glutathione with a
number of electrophilic compounds (Kanaoka et al., 2000;
Inoue et al., 2003; Flanagan and Smythe, 2011). GSTs have
also been linked to a number of neurodegenerative diseases.
In post-mortem brain samples of Alzheimer’s disease patients,
GST activity and protein levels were significantly decreased,
1https://www.wormbase.org/species/c_elegans/gene/WBGene00001752#0-9f-3
(accessed September 7, 2019).
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especially in the amygdala, the hippocampus, the inferior parietal
lobule and the nucleus basalis of Meynert (Lovell et al., 1998).
Furthermore, in a Drosophila PD model, genetic studies revealed
that parkin mutants with additional (loss-of-function) mutations
of GSTS1 genes [a sigma class GST (Singh et al., 2001)] caused a
worse neurodegenerative phenotype than the parkin mutant itself
(Whitworth et al., 2005). On the other hand, over-expression of
GSTS1 in DAergic neurons suppressed neurodegeneration and
hence, suggested a protective effect of these antioxidant enzymes
in PD. Whether GST-4 in C. elegans has the same bifunctionality
as seen for HPGDS is so far unclear and needs further research.
Despite the accumulation of evidence confirming the role
of oxidants in several pathological conditions, most of the
antioxidants developed for clinical use have been proven
inconclusive or demonstrated limited success. This could be due
to the fact that clinical trials include patients at broad stages
of disease and therefore distinct severity of symptoms, as well
as from different environmental and genetic backgrounds (Pohl
and Kong Thoo Lin, 2018). The investigation of other sources
of antioxidants, like RSP, and their application in earlier stages
of disease progression and/or as a therapeutic adjuvant, as well
as a closer monitoring of clinical trial design may improve
therapeutic outcomes.
In conclusion, the RSP extract was shown to have positive
effects in vivo in C. elegans models in a GST-4 dependent manner.
This enzyme could constitute a viable therapeutic target for
neurodegenerative diseases. For validation of this hypothesis
prospective studies on the use of RSP extract or of the single
compounds most prevalent in the extract, i.e., sinapine in
vertebrate models of MJD and PD in comparison to other plant
extracts should be conducted.
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Name Synonym Genotype origin
Wild type N2 wt CGCa
AM510 AT3q14 rmIs228[PF25B3.3::AT3v1-
1q14::yfp]
(Teixeira- Castro et al.,
2011)
AM685 AT3q130 rmls263[PF25B3.3::AT3v1-
1q130::yfp] II
(Teixeira- Castro et al.,
2011)
BZ555 Pdat-1::GFP egIs1 [dat-1p::GFP] CGCa
UA44 ɑ-syn baIn11[pdat-1::aSyn + pdat-
1::GFP]
Caldwell Labb
UA57 CAT-2 baIs4 [dat-1p::GFP + dat-
1p::CAT-2]
Caldwell Labb
RB1823 gst-4(ko) gst-4&msp-38(ok2358) IV. CGCa (6x backcrossed, this
study)
CF1553 sod-3 muIs84 [(pAD76) sod-
3p::GFP + rol-6(su1006)]
CGCa
LD1171 gcs-1 ldIs3 [gcs-1p::GFP + rol-
6(su1006)]
CGCa
CL2166 gst-4 dvIs19 [(pAF15)gst-
4p::GFP::NLS] III
CGCa
MAC146 AT3q130;gst-4(ko) rmls263[PF25B3.3::AT3v1-
1q130::yfp] II; gst-4&msp-
38(ok2358) IV
This study
MAC148 ɑ-syn; gst-4(ko) baIn11[pdat-1::aSyn + pdat-
1::GFP]; gst-4&msp-
38(ok2358) IV
This study
Supplementary data
Tables S1: C. elegans strains employed
Note(s): aCGC, funded by NIH Office of Research Infrastructure Programs (P40 OD010440); bGuy and Kim Caldwell, The University of Alabama
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Figure S1| Effect of sinapine on C. elegans (A) Sinapine (0.001-1.0 mg/mL) shows no toxic effect in
C. elegans. Toxicity was assessed using the food clearance assay. The optical density of the OP50
suspension with RSP extract-treated animals (N2) at the concentrations depicted, was measured
daily. The mean OD was calculated for each day from triplicate samples and plotted over time.
Control DMSO (1%) corresponds to drug vehicle and DMSO at 5% was used as positive (toxic
compound) control, n=6. (B) Locomotion defective behavior of MJD (AT3q130) animals, comparison
between treated (sinapine 0.001-1.0 mg/mL), untreated animals (1% DMSO solvent control), wild
type (N2) and AT3q14 controls (1% DMSO). Statistical significant difference was determined using
One-way ANOVA and Dunnett’s multiple comparison analysis compared to AT3q130 control:
***p≤0.001, *p≤0.05; n=4
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Figure S1| 6-OHDA dependent DAergic neurodegenation differs between DAergic neuron classes. 
Total number of DAergic neurons per class were scored for each condition. Data are expressed as 
the median ± 10-90 percentile, with results obtained from three independent experiments (n= 3 
with ≥10 animals per treatment). Significant differences between conditions were determined by 
non-parametric Kruskal-Wallis test and outlier analysis. ## p<0.01, ###p<0.001 compared with 
vehicle alone (no 6-OHDA); **p<0.01 and ***p<0.001 compared with respective 6-OHDA 
concentration control. 6-OHDA: 6-hydroxydopamine; DAergic-dopaminergic neurons 
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